Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | NCS1 | P62166 | 1/20 | 0.64 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.63 |
| ▸ | FES | P07332 | 1/20 | 0.63 |
| ▸ | PIM1 | P11309 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | GSK3A | P49840 | 1/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.63 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.63 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.63 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.63 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.63 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.63 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17770524 | 0.89 | KDM4E (0.55) | KDM4EGAANPSR1RXFP1NCS1 | |
| SCHEMBL24044886 | 0.88 | CSNK1D (0.56) | KDM4EGAANPSR1RXFP1NCS1 | |
| SCHEMBL27365053 | 0.88 | NCS1 (0.60) | KDM4EGAANPSR1RXFP1NCS1 | |
| SCHEMBL17770554 | 0.87 | MAPT (0.77) | KDM4EGAANPSR1RXFP1DCLK1 | |
| SCHEMBL19631005 | 0.86 | CSNK1D (0.55) | KDM4EGAANPSR1RXFP1NCS1 | |
| SCHEMBL30472744 | 0.85 | CSNK1D (0.62) | MAP4K5CSNK1DDYRK1AACP1 | |
| SCHEMBL17770389 | 0.85 | CSNK1D (0.62) | MAP4K5CSNK1DDYRK1AACP1 | |
| SCHEMBL19612158 | 0.85 | KDM4E (0.54) | KDM4EGAANPSR1RXFP1NCS1 | |
| SCHEMBL19630768 | 0.85 | CSNK1D (0.55) | KDM4EGAANPSR1RXFP1NCS1 | |
| SCHEMBL19612122 | 0.84 | DYRK1A (0.57) | KDM4EGAANPSR1RXFP1NCS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319516-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-09 | — | — | US | disclosed |
| US-20170319516-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-09 | — | — | US | disclosed |
| EP-3220904-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Rutgers, the State University of New Jersey (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081599-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081599-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319516-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | HADHA, HADHB, TFAM | KDM4E 800/4885GAA 1318/4885NPSR1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.